Annual treatment cost analysis for nintedanib

Nintedanib (Nintedanib) is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung disease (ILD) and systemic sclerosis-associated interstitial lung disease (SSc-ILD). The drug can effectively slow down the damage of lung tissue and help patients improve lung function. When using nintedanib, it must be done under the professional guidance of a doctor. The recommended regular dose is 150mg, taken orally twice a day, with an interval of about 12 hours between drugs. Due to individual differences among patients and different medication regimens, multiple factors need to be taken into consideration when calculating the cost of medication for one year.

In the Chinese market, the common packaging specifications of nintedanib are150mg*30 capsules/box, and the market price is approximately RMB 4,000. Based on the recommended dosing regimen, patients typically require two boxes of medication in a month. If the patient continues to take the medication at the recommended dosage, the drug cost for a year will exceed 90,000 yuan. It should be noted that this cost is only an estimate, and the actual situation may vary depending on the region, pharmacy pricing, and medical insurance reimbursement policies.

In the international market, the selling price of nintedanib’s original drug in some countries, such as Türkiye and India, is similar to the domestic price. In addition, generic drugs are also an economical option for patients to consider. For example, the price of some 150mg*30-capsule generic drugs from Laos is usually around 600 yuan. For patients with limited financial resources, choosing generic drugs can significantly reduce the cost of treatment. If generic drugs are mainly used, the patient's monthly drug cost may be reduced to more than 1,000 yuan. After calculation, the total cost per year is about 10,000 yuan. This provides a more feasible treatment option for many patients.

Reference materials:https://www.mayoclinic.org/drugs-supplements/nintedanib-oral-route/description/drg-20122674